Virtu Financial LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 8,782 shares of the life sciences company's stock, valued at approximately $1,173,000.
A number of other institutional investors have also recently made changes to their positions in the company. Empowered Funds LLC increased its holdings in shares of Illumina by 1.7% in the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company's stock worth $516,000 after buying an additional 66 shares during the last quarter. Bank of Stockton increased its stake in Illumina by 3.8% during the fourth quarter. Bank of Stockton now owns 2,162 shares of the life sciences company's stock worth $289,000 after acquiring an additional 80 shares during the last quarter. Caprock Group LLC raised its position in Illumina by 3.0% during the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company's stock valued at $376,000 after purchasing an additional 83 shares during the period. Stephens Inc. AR lifted its stake in shares of Illumina by 1.4% in the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company's stock valued at $885,000 after purchasing an additional 90 shares during the last quarter. Finally, Spire Wealth Management boosted its holdings in shares of Illumina by 26.0% in the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company's stock worth $63,000 after purchasing an additional 97 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.
Illumina Stock Down 0.7 %
ILMN traded down $0.55 on Thursday, hitting $82.28. The company had a trading volume of 1,812,730 shares, compared to its average volume of 2,106,132. The stock has a market capitalization of $13.03 billion, a price-to-earnings ratio of -10.71, a P/E/G ratio of 1.60 and a beta of 1.17. The stock has a fifty day moving average price of $105.03 and a 200-day moving average price of $127.40. Illumina, Inc. has a 12-month low of $80.18 and a 12-month high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.
Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on ILMN shares. Guggenheim decreased their price target on Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a report on Friday, February 7th. HSBC lowered shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 target price for the company. in a report on Friday, February 28th. Citigroup cut their price target on shares of Illumina from $130.00 to $90.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Royal Bank of Canada cut their target price on Illumina from $247.00 to $128.00 and set an "outperform" rating on the stock in a research note on Wednesday, March 12th. Finally, Hsbc Global Res downgraded Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $140.90.
Check Out Our Latest Report on Illumina
Illumina Company Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Stories
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
